Furthermore, BKM120 (a pan-PI3K inhibitor) treatment resulted in a significant decrease in the proliferative capacity in PAICS knockdown EGFR-Mut NSCLC cells, suggesting that activated PI3K-AKT signaling may impair the effects of PAICS knockdown [27]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.